Litigation Risk Related to Adverse Events, Product Liability and Intellectual Property
First written in FY2016. 2 of 5 entries say "Restated". Latest entry: FY2022-Q2.
Seikagaku moved to the "Worse" side of this theme in 2021.
The whole theme swung hardest in 2021: 1 of 6 companies on the "Worse" side.
5 other companies' latest entry also says "Restated".
- FY2022-Q2RestatedAnnual report
「Because multiple cases of shock and anaphylaxis were reported following administration of this drug, the Company issued a safety alert (Blue Letter) for healthcare professionals on 1 June of the same year.」
Reports of shock and anaphylaxis after administration of JOYCLU and the issuance of a safety alert are restated. - FY2022-Q1MaterialisedAnnual report
「Because multiple cases of shock and anaphylaxis were reported following administration of this drug, the Company issued a safety alert (Blue Letter) for healthcare professionals on 1 June of the same year.」
Following reports of shock and anaphylaxis after administration of JOYCLU, the fact that a safety alert was issued is restated. - FY2021MaterialisedAnnual report
「With multiple cases of anaphylaxis reported in patients following administration of Joyclu, a joint function improvement agent, the Company issued a safety alert for healthcare professionals, is collecting and analyzing adverse events, and has strengthened its safety monitoring activities.」
Regarding the risk of side effects, multiple cases of anaphylaxis were reported following administration of Joyclu, leading to the issuance of a safety alert and the strengthening of safety monitoring activities. - FY2017RestatedAnnual report
「In conducting its business, if the Company becomes subject to litigation concerning pharmaceutical side effects, product liability, intellectual property rights such as patents, labor issues or other matters, business performance may be affected depending on the nature of the claims.」
Reiterates the risk of litigation concerning side effects, product liability, intellectual property rights, labor issues and other matters. - FY2016First statedAnnual report
「If the Company becomes subject to litigation concerning pharmaceutical side effects, product liability, intellectual property rights such as patents, labor issues or other matters, business performance may be affected depending on the nature of the claims.」
Lists multiple types of litigation associated with the pharmaceutical business as risks to business performance.